Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LPHN2
REST API REST API
Homo sapiens
LPHN2 is differentially expressed in 255 experiments: 145 organism parts: lung, bone marrow, ... (143 more);, 212 disease states: normal, control, ... (210 more);, 80 cell types 397 cell lines 34 compound treatments and 65 other conditions.
Synonyms LPHH1, LEC1, KIAA0786
Orthologs Lphn2 (Mus musculus)   F7BLT2_CIOIN (Ciona intestinalis)   F6W108_CIOIN (Ciona intestinalis)   F1NN37_CHICK (Gallus gallus)   LPHN2 (1 of 2) (Danio rerio)   F1MZ71_BOVIN (Bos taurus)   LPHN2 (2 of 2) (Danio rerio)   Lphn2 (Rattus norvegicus)   LPHN2 (Xenopus laevis)   LPHN2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term sugar binding, plasma membrane, protein binding, G-protein coupled receptor activity, neuropeptide signaling pathway, membrane, G-protein coupled receptor protein signaling pathway, synaptosome, signal transducer activity, cell surface receptor linked signaling pathway, receptor activity, integral to membrane, PDZ domain binding, brain development, latrotoxin receptor activity, transmembrane signaling receptor activity
InterPro Term GPS_dom, GPCR_2-like, Olfac-like, GPCR_2_extracellular_dom, GPCR_2_secretin-like, GPCR_2_latrophilin_rcpt_C, GPCR_2_latrophilin, Lectin_gal-bd_dom, DUF3497
UniProt Accession Q9UJ49, A8MW65, O95490, B1ALU6, B1ALU5, B1ALU4, B1ALU2, B1ALU3, B1ALU1, E7ERX4
Search EB-eye ENSG00000117114
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (38 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
391 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, E-GEOD-20677, ... (40 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-MEXP-66, E-GEOD-7307
fibroblast
2
E-GEOD-3920, E-MEXP-466
whole blood
2
E-MTAB-25, E-GEOD-3026
adult choroid from 76 y.o. donor
1
E-GEOD-18811
multipotent adult progenitor cell
1
E-MEXP-466
neurosphere cell
1
E-MEXP-551
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-GEOD-12254, ... (59 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-TABM-26
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-GEOD-5823
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-37, E-MEXP-231
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602, E-GEOD-20295
mesothelioma
2
E-MTAB-37, E-MTAB-62
206 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-1417, E-GEOD-5824, E-MEXP-2590, E-MEXP-941, ... (19 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
none
2
3
E-GEOD-5824, E-GEOD-412, E-GEOD-7307, E-GEOD-1417, E-GEOD-2803 ... (5 experiments)
TTA
1
E-MEXP-2590
mercaptopurine, methotrexate
1
E-GEOD-412
vanadium pentoxide
1
E-GEOD-5339
control - keratinocyte growth factor
1
E-GEOD-7216
28 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
58
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-7967, E-TABM-125, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-19665, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (32 experiments)

Infection
studied in E-GEOD-12254

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM